Head to Head Contrast: Compass Therapeutics (NASDAQ:CMPX) & Oric Pharmaceuticals (NASDAQ:ORIC)

Oric Pharmaceuticals (NASDAQ:ORIC) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Valuation & Earnings

This table compares Oric Pharmaceuticals and Compass Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$127.85 million	($1.73)	-6.02
Compass Therapeutics	$850,000.00	1,364.29	-$49.38 million	($0.45)	-14.49

Compass Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Compass Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Oric Pharmaceuticals has a beta of 1.35, suggesting that its stock price is 35% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500.

Institutional & Insider Ownership

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 6.8% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 29.8% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Oric Pharmaceuticals and Compass Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-45.33%	-41.78%
Compass Therapeutics	N/A	-48.89%	-42.47%

Analyst Ratings

This is a summary of recent recommendations and price targets for Oric Pharmaceuticals and Compass Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1	2	11	0	2.71
Compass Therapeutics	1	0	13	1	2.93

Oric Pharmaceuticals presently has a consensus price target of $19.90, suggesting a potential upside of 90.98%. Compass Therapeutics has a consensus price target of $12.46, suggesting a potential upside of 91.13%. Given Compass Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than Oric Pharmaceuticals.

Summary

Compass Therapeutics beats Oric Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

About Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.